1 Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel

- 2 Coronavirus Disease 2019 in Hefei, China
- 3 Zonghao Zhao^{1, a}, Jiajia Xie^{2, a}, Ming Yin^{3, 4, a}, Yun Yang^{3, 4}, Hongliang He¹, Tengchuan Jin⁵,
- 4 Wenting Li¹, Xiaowu Zhu⁶, Jing Xu¹, Changcheng Zhao⁷, Lei Li¹, Yi Li¹, Hylemariam
- 5 Mihiretie Mengist⁵, Ayesha Zahid⁵, Ziqin Yao¹, Chengchao Ding⁸, Yingjie Qi⁷, Yong Gao⁹,
- 6 Xiaoling Ma^{7*}
- 7 Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life
- 8 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
- 9 230001, China;
- 10 ² Department of Dermatology, The First Affiliated Hospital of USTC, Division of Life
- 11 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
- 12 230001, China;
- ³ Department of ICU, The First Affiliated Hospital of USTC, Division of Life Sciences and
- Medicine, University of Science and Technology of China, Hefei, Anhui, 230000, China;
- 15 ⁴ Department of ICU, Hefei Infectious Diseases Hospital, Hefei, Anhui, 230000, China;
- ⁵ Laboratory of Structural Immunology, Division of Life Sciences and Medicine, University
- of Science and Technology of China (USTC), Hefei, Anhui, 230027, China;
- 18 6 Department of Infectious Diseases, Hefei Infectious Diseases Hospital, Hefei, Anhui,
- 19 230000, China;
- ⁷ Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life
- 21 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui,
- 22 230001, China;
- 23 8 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University
- of Science and Technology of China, Hefei, Anhui, 230001, China;
- ⁹ Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life
- 26 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 230000, China.

28

- ^a The first author of this article.
- ^{*} Corresponding Author: Yong Gao, Department of Infectious Diseases, The First Affiliated
- 31 Hospital of USTC, Division of Life Sciences and Medicine, University of Science and
- Technology of China, Hefei, Anhui, 230000, China (ygao387@ustc.edu.cn).
- 33 Xiaoling Ma, Department of Laboratory Medicine, The First Affiliated Hospital of USTC,
- 34 Division of Life Sciences and Medicine, University of Science and Technology of China,
- 35 Hefei, Anhui, 230001, China (xiaolingma@126.com).

Abstract

36

53

37 The outbreak of the novel coronavirus disease 2019 (COVID-19) infection began in December 2019 in Wuhan, and rapidly spread to many provinces in China. The 38 39 number of cases has increased markedly in Anhui, but information on the clinical characteristics of patients is limited. We reported 75 patients with COVID-19 in the 40 First Affiliated Hospital of USTC from Jan 21 to Feb 16, 2020, Hefei, Anhui Province, 41 China. COVID-19 infection was confirmed by real-time RT-PCR of respiratory 42 nasopharyngeal swab samples. Epidemiological, clinical and laboratory data were 43 44 collected and analyzed. Of the 75 patients with COVID-19, 61 (81.33%) had a direct or indirect exposure history to Wuhan. Common symptoms at onset included fever 45 (66 [88.0%] of 75 patients) and dry cough (62 [82.67%]). Of the patients without 46 47 fever, cough could be the only or primary symptom. The most prominent laboratory abnormalities were lymphopenia, decreased percentage of lymphocytes (LYM%), 48 decreased CD4+ and CD8+ T cell counts, elevated C-reactive protein (CRP) and 49 lactate dehydrogenase (LDH). Patients with elevated interleukin 6 (IL-6) showed 50 significant decreases in the LYM%, CD4+ and CD8+ T cell counts. Besides, the 51 52 percentage of neutrophils, CRP, LDH and Procalcitonin levels increased significantly.

We concluded that COVID-19 could cause different degrees of hematological

- abnormalities and damage of internal organs. Hematological profiles including LYM,
- 55 LDH, CRP and IL-6 could be indicators of diseases severity and evaluation of
- treatment effectiveness. Antiviral treatment requires a comprehensive and supportive
- 57 approach. Further targeted therapy should be determined based on individual clinical
- 58 manifestations and laboratory indicators.
- 59 **Keywords:** coronavirus disease 2019, clinical profile, hematological abnormality,
- 60 interleukin 6

Introduction

- 62 Since Dec 2019, a series of acute respiratory illness outbreaks in Wuhan, Hubei
- Province, China [1, 2]. The disease has been subsequently identified in other
- provinces in China, and other counties. On Jan 7, a novel coronavirus was identified
- by deep sequencing analysis of samples from throat swabs and lower respiratory tract.
- The disease caused by the novel virus is now named by WHO as novel coronavirus
- disease 2019 (COVID-19). Epidemiological research shows that all infected patients
- 68 had travel or residence records in Wuhan, suggesting the possibility of
- 69 person-to-person transmission [3]. By Feb 22, 2020, more than 75,000 confirmed
- cases, including 1716 health-care workers, have been identified in China. And 989
- 71 patients have been diagnosed in Anhui Province, including 6 deaths.
- The novel coronaviruse is an enveloped non-segmented positive sense RNA virus
- belonging to the betacoronaviruses. The well-known atypical pneumonia virus
- 74 (SARS-CoV) and Middle East Respiratory Syndrome Virus (MERS-CoV) are also
- betacoronaviruses [4]. Clinical manifestations of COVID-19 include fever, dry cough,
- myalgia and fatigue. Symptoms of headache, expectoration, and diarrhea seem to less
- 77 common. Radiographic evidence suggested pneumonia. About half of patients have
- developed severe pneumonia. Nearly one third of patients require intensive care
- 79 because of acute respiratory distress syndrome (ARDS) or multiple organ failure [1,
- 80 5].

81

At present, there are relatively few reports about novel coronavirus pneumonia in

- 82 Anhui Province. Here, we described the epidemiological, clinical and laboratory
- characteristics of 75 COVID-19 confirmed patients admitted to the First Affiliated
- Hospital of USTC, Hefei. This study will be beneficial for the diagnosis and treatment
- of COVID-19 patients in clinical practice.

Methods

86

87

88

89

90

91

92

93

94

95

96

97

98

Patients

In this study, we eventually enrolled 75 patients from the First Affiliated Hospital of USTC between Jan 21, and Feb 16, 2020. Most patients came to the hospital because of fever or respiratory symptoms. Our clinical team consulted and recorded their epidemiological history in detail regarding to whether they had been to Wuhan or exposed to people who came from Wuhan recently. Nasopharyngeal and throat swabs were taken for respiratory pathogens test. The physical findings, hematological, biochemical and radiological results were also recorded. All patients were identified as laboratory-confirmed COVID-19 infection. All patients enrolled in this study were diagnosed according to World Health Organization interim guidance. The study was approved by the Ethics Committee of the First Affiliated Hospital of USTC.

Procedures

99 Respiratory nasopharyngeal swabs were collected and the presence of COVID-19 was detected by next real-time RT-PCR methods. Viral RNA was extracted using 100 QIAamp RNA virus Kit (Qiagen, Heiden, Germany). The diagnostic test was done 101 102 using a commercial coronavirus test kit (Shenzhen Huada Yinyuan Pharmaceutical Technology Co., Ltd., Shenzhen). The specific primers and probe targeted to 103 104 nucleocapsidprotein (N) were used and the sequences were as follows: forward primer 5'-GGGGAACTTCTCCTGCTAGAAT-3'; primer 105 reverse 5'-CAGACATTTTGCTCTCAAGCTG-3'; 106 and the probe 107 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. Conditions for the amplifications were 50°C for 20 min, 95°C for 10 min, followed by 40 cycles of 108 109 denaturation at 95°C for 15 s and extending and collecting fluorescence signal at 60°C

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

for 30 s. A cycle threshold value (Ct-value) less than 37 was defined as a positive test result, and a Ct-value of 40 or more was defined as a negative test. A medium load, defined as a Ct-value of 37 to less than 40, requires a retesting according to the guideline of Chinese Centers for Disease Control and Prevention (http://ivdc.chinacdc.cn/kyjz/202001/t20200121 211337.html). We also examined other respiratory viruses, including influenza, avian influenza, respiratory syncytial virus, adenovirus, parainfluenza virus, SARS-CoV and MERS-CoV, with realtime RT-PCR. Hematological parameters including blood routine, blood biochemistry, coagulation profile, and infection-related biomarkers were recorded. Plasma cytokine interleukin 6 (IL-6) levels were detected by ELISA. And the CD4⁺ and CD8⁺ T cell subsets were counted using flow cytometry. Statistical analysis We presented continuous measurements as median (IQR) and categorical variables as number (%). Continuous variables were analyzed using the Mann-Whitney test. For laboratory results, we also assessed whether the measurements were outside the normal range. Graphpad prism 8.3 was used for all analyses. A two-sided α of less than 0.05 was considered statistically significant. **Results** Totally, 75 patients diagnosed with COVID-19 were included in this study. Among them, 61 (81.33%) patients had been to Wuhan or exposed to people who came from Wuhan. The median age of the patients was 47 years. Among them, 36 (48%) were aged 40-59 years, 25 (33.3 %) were aged 20-39 years, 11 (14.67%) were aged 60-79 years. The youngest patient aged 16 years and the oldest aged 91 years. More than half of the participants were men (42 [56%]). Twenty-nine (38.67%) patients had one or more chronic diseases, including cardiovascular and cerebrovascular disease, diabetes, chronic kidney disease, respiratory system disease, nervous system disease, chronic liver diseases, and malignant tumor (Table 1).

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

Most patients admitted to hospital because of fever (66 [88.0%]) and dry cough (62 [82.67%]). Nearly a third of patients had chest tightness (24 [32.0%]). And 20 (26.67%) patients had all the three symptoms mentioned above. Less common symptoms included sputum production (22 [29.33%]), fatigue (17 [22.67%]), muscle soreness (9 [12.0%]) and poor appetite (9 [12.0%]). Other symptoms included diarrhea, sore throat, headache, shortness of breath and stomach ache. Nine patients had a body temperature below 37.3°C, and all of them had symptom of dry cough. Only a small proportion had sputum, fatigue, poor appetite and chest tightness (Table 2). The blood counts of patients on admission showed leucopenia (white blood cell counts below the normal range; 12 [16.0%]). Twenty-nine (38.67%) patients showed increased neutrophil percentage (NEU%). Over half of the patients (40 [53.33%]) showed lymphopenia (lymphocytes counts less than 1.1×10^9 /L). However, no patients had increased lymphocytes counts. Thirty-one (41.33%) and 28 (37.33%) patients showed decreased counts of CD4+ and CD8+ T cell levels, respectively. The CD4⁺/CD8⁺ ratio was below the normal range in 11 (14.67%) patients. Haemoglobin were decreased in 11 (14.67%) patients and increased in 18 (24%) patients. Platelets were below the normal range in 14 (18.67%)) patients and above the normal range in only 2 (2.67%) patients. Most patients showed impaired coagulation function. Activated partial thromboplastin time (APTT) was longer in 44 (58.67%) patients and prothrombin time (PT) was longer in 30 (40%) patients (Table 3). Fifteen patients had differing degrees of liver function abnormality, with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the normal range. One patient with no underlying disease had a serious liver function damage (ALT 171 U/L, AST 60 U/L). Nearly half of patients showed abnormal myocardial zymogram, with the elevation of lactate dehydrogenase (LDH) in 33 (44%) patients and the elevation of Troponin I in 13 (17.33%) patients. Fifteen (20%) patients had different degrees of renal function damage with elevated serum creatinine. One patient with uremia had creatinine level of 1561 µmol/L (Table 3). These findings suggested that

the internal organs could also be potential targets of COVID-19.

Regarding the infection index, most patients showed elevated C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) levels. Procalcitonin (PCT) was elevated in 2 out of 59 patients. Forty-nine patients were tested for IL-6, and 14 (28.57%) of them showed levels above the normal range (Table 3). Further analysis showed that the 14 patients had significant decreases in lymphocytes percentage, CD4⁺ and CD8⁺ T cell counts, compared to those with normal IL-6 range. Besides, the NEU%, CRP and LDH levels increased significantly (Table 4; Figure 1). PCT values were within normal range in both two groups. These data indicated that there might be correlation between the increased IL-6 level and the severity of viral infection. And we will continue paying attention to this point in the future.

Discussion

This report, to our knowledge, is the first case series of patients with COVID-19 in Anhui Province. As most patients remain hospitalized, we focus on the clinical and laboratory profiles upon their admission. Epidemiological research shows that most patients have been to Wuhan recently. Common symptoms were fever, cough, and chest tightness. However, a significant proportion of patients presented with atypical symptoms such as fatigue, muscle soreness and diarrhea. We also pay attention to patients without fever in which cough may be the only or primary symptom. Therefore, to avoid further transmission, screening and closely monitoring of each suspect remain important. Further studies on the epidemiological characteristics of these atypical cases are recommended.

The most common laboratory abnormalities observed in this study were decreased total lymphocytes, prolonged APTT, elevated LDH, CRP and ESR. Similarities abnormalities between COVID-19 and previously observed betacoronavirus, MERS-CoV and SARS-CoV infection, have been noted [3, 6, 7]. These findings suggest that COVID-19 can cause different degrees of hematological abnormalities and damage of internal organs. The absolute value of lymphocytes was reduced in

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

more than 50% patients. The most significant was the decreased CD4⁺ T cell counts. Previous studies of patients in Wuhan suggested virus invasion could induce a cytokine storm syndrome (CRS) [5, 8]. Of the 14 patients with elevated IL-6, LYM%, CD4⁺ and CD8⁺ T cell counts were significantly decreased and NEU%, CRP and LDH levels increased significantly. Elevated IL-6 may be an important factor leading to T lymphocytes damage and cellular immune deficiency. IL-6 could also be used as an indicator to evaluate infection severity. Therefore, we conclude that IL-6 may be an effective target for prevention or treatment of serve COVID-19 infection. Future large-scale studies are needed to clarify the underlying mechanisms of disease pathogenesis. COVID-19 belongs to the betacoronavirus. As a single-stranded positive-sense RNA virus, COVID-19 has 79.5% homology with SARS-CoV [9]. Similar to SARS-CoV, angiotensin converting enzyme II (ACE2) is also the cellular entry receptor of COVID-19 [9, 10]. ACE2 is highly expressed in human lung tissue, gastrointestinal tract, vascular endothelial cells and arterial smooth muscle cells [11]. Therefore, all of the organs above may be targets for virus attack. ACE2 effectively hydrolyzes the potent vasoconstrictor angiotensin II to angiotens and is related to hypertension, cardiac function and diabetes [12]. Liu et al. discovered that the Angiotensin II level in the plasma samples increased markedly, suggesting that COVID-19 could induce imbalanced renin-angiotensin system. Drugs of ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) may be used as potential treatment of COVID-19 infection [13]. As we can see, in patients with underlying diseases, most of them have hypertension. However, no report has focused on the correlation between antihypertensive agents with COVID-19 infection or disease severity. Studies are necessary to evaluate the effectiveness of ACEI and ARB in the future. Currently, there is no specific therapy for patients with new coronavirus pneumonia. The pathologic mechanisms of disease progression and exacerbation are also unclear. How to relieve the clinical symptoms of critically ill patients, and reduce the severity

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

and mortality of patients still remains challenging. Considering the similarities between SARS-CoV and COVID-19, some pre-clinical drugs against SARS-CoV have been applied to COVID-19 patients. Remdesivir (RDV), a broad-spectrum antiviral nucleotide analogue, is reported to treat MERS-CoV and SARS-CoV infections effectively [14, 15]. A randomized controlled trial was initiated to determine the safety and efficacy of RDV in patients with COVID-19 in Wuhan, China recently. It is crucial to determine host tropism and transmission capacity in terms of prevention of the virus infection [16]. Spike (S) protein mediates membrane fusion through binding with ACE2. Monoclonal antibody against the S protein may efficiently block the virus from entering the host. Convalescent plasma had also been reported to be clinically useful to SARS and MERS patients [17, 18]. If available, convalescent plasma should be used for critically ill patients with COVID-19. However, the appearance of therapeutic plasma requires time and exists only in recovered patients. In our opinion, comprehensive and supportive treatments are essential in the early stage. Additionally, antiviral treatment in early stage and immune activation blockers such as IL-6 blockers, IL-1 blockers in late stage could be tried to control further disease progress leading to ARDS due to excessive immune activation. Targeted treatment should depend on individual differences due to various disease characteristics. This study has several limitations. First, only 75 patients with confirmed COVID-19 were included. It would be better to include as many patients as possible to get a more comprehensive understanding of COVID-19. Second, more detailed patient information, particularly treatment strategies and clinical outcomes, was unavailable at the time of analysis. Regarding the inflammatory factors, we only measured IL-6 level changes. Future studies should focus on changes of various pro-inflammatory factors, ie IL-1, which may provide precise target treatment options for different patients. In conclusion, this study provides an early assessment of the clinical and laboratory profiles of COVID-19 patients in Hefei, China. The clinical manifestation of

COVID-19 was nonspecific. Specific coronavirus antivirals show proven efficacies in 252 humans are unavailable to date. Antiviral therapy requires a comprehensive and 253 supportive treatment. Targeted therapy should also be determined based on individual 254 clinical manifestations and laboratory indicators. 255 256 **Funding** This work is funded by the Key Research and Development Plan Project of Anhui 257 Science and Technology Department (YG, No. 201904b11020044). 258 **Contributors** 259 ZZ and MY collected the epidemiological and clinical data. JJX contributed to the 260 statistical analysis and drafted the manuscript. YY, TJ, HM, and AZ revised the final 261 manuscript. HH, WL, ZY, XZ, JX, CZ, LL, YL, CD and YQ contributed to clinical 262 and laboratory data acquisition. YG and XM had the idea for the study and take 263 responsibility for the integrity of the data and the accuracy of the data analysis. 264 Acknowledgements 265 We acknowledge all health-care workers involved in the diagnosis and treatment of 266 patients in Hefei. We thank the Chinese National Health Commission for coordinating 267 data collection for patients with COVID-19. 268 **Declaration of interests** 269 We declare no competing interests. 270 **References:** 271 272 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus 273 in Wuhan, China. Lancet (London, England) 2020 2020-01-01. 274 2. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel

coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. INT J

275

276

INFECT DIS 2020;91:264-6.

- 277 3. Chan JF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel
- 278 coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet
- **279 2020**;395(10223):514-23.
- 280 4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China,
- 281 2019. N Engl J Med **2020** 2020-01-24.
- 282 5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019
- 283 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020
- 284 2020-01-01;395(10223):507-13.
- 285 6. Ko JH, Park GE, Lee JY, et al. Predictive factors for pneumonia development and progression to
- respiratory failure in MERS-CoV infected patients. J Infect 2016 2016-11-01;73(5):468-75.
- 287 7. Liu CL, Lu YT, Peng MJ, et al. Clinical and laboratory features of severe acute respiratory
- 288 syndrome vis-a-vis onset of fever. CHEST **2004** 2004-08-01;126(2):509-17.
- 289 8. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
- 290 Coronavirus Infected Pneumonia in Wuhan, China. JAMA 2020 2020-02-07.
- 9. Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of
- 292 probable bat origin. NATURE **2020** 2020-02-03.
- 293 10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from
- Wuhan: An analysis based on decade-long structural studies of SARS. J VIROL 2020 2020-01-29.
- 295 11. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2
- protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.
- 297 J PATHOL **2004** 2004-06-01;203(2):631-7.
- 298 12. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and
- 299 cellular perspective. CELL MOL LIFE SCI **2004** 2004-11-01;61(21):2704-13.
- 300 13. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected
- patients linked to viral loads and lung injury. Science China Life Sciences **2020** 2020-02-09.
- 302 14. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both

epidemic and zoonotic coronaviruses. SCI TRANSL MED 2017 2017-06-28;9(396). 15. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. NAT COMMUN 2020 2020-01-10;11(1):222. 16. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 2020. 17. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016 2016-03-01;14(2):152-7. 18. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 2005-01-01;24(1):44-6.

Table 1. Demographics and baseline characteristics of 75 patients infected with

COVID-19

324

Characteristics	No. (%)
Age, years, Median (IQR)	47 (34-55)
Range	16-91
<20	1 (1.33%)
20-39	25 (33.33%)
40-59	36 (48.00%)
60-79	11 (14.67%)
≥80	2 (2.67%)
Sex	
Female	33 (44%)
Male	42 (56%)
Exposure to Wuhan people	61 (81.33%)
Chronic medical illness	29 (38.67%)
Cardiovascular and cerebrovascular diseases	16 (21.33%)
Diabetes	6 (8.00%)
Chronic kidney disease	4 (5.33%)
Chronic liver disease	4 (5.33%)
Respiratory system disease	2 (2.67%)
Nervous system disease	1 (1.33%)
Malignant tumour	1 (1.33%)

326 Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.

Data are presented as median (IQR) or n/N (%). N is the total number of patients with available

data.

327

328

329

330

Table 2. Signs and symptoms of patients with COVID-19

Signs and symptoms	No. (%)
Fever (°C)	
<37.3	9 (12.00%)
37.3-38.0	32 (42.67%)
38.1-39.0	32 (42.67%)
>39.0	2 (2.67%)
Dry cough	62 (82.67%)
Chest tightness	24 (32.00%)
Sputum production	22 (29.33%)
Fatigue	17 (22.67%)
Muscle soreness	9 (12.00%)
Poor appetite	9 (12.00%)
Diarrhea	7 (9.33%)
Sore throat	6 (8.00%)
Headache	5 (6.67%)
Shortness of breath	2 (2.67%)
Stomach ache	1 (1.33%)
Fever, cough and chest tightness	20 (26.67%)

Patients without fever (<37.3°C)	9
Dry cough	9 (100.0%)
Sputum production	2 (22.2%)
Fatigue	2 (22.2%)
Poor appetite	2 (22.2%)
Chest tightness	1 (11.1%)

Data are presented as n/N (%). N is the total number of patients with available data.

Table 3. Laboratory results of patients infected with COVID-19 on admission to hospital

Blood routine	Median (IQR)	Minimum	Maximum	Increased	Decreased
Leucocytes (×10^9 per L; normal range					
3.5-9.5)	5.38(4.06-6.77)	2.01	16.53	4 (5.33%)	12 (16%)
Neutrophils (×10^9 per L; normal range					
1.8-6.3)	3.54 (2.22-5.3)	1.09	14.43	9 (12%)	11 (14.67%)
Percentage of neutrophils (%; normal					
range 40-75)	69.70 (58.45-79.18)	29.38	91.61	29 (38.67%)	4 (5.33%)
Lymphocytes (×10^9 per L; normal rang	e				
1.1-3.2)	1.07 (0.68-1.53)	0.32	3.03	0 (0%)	40 (53.33%)
Percentage of Lymphocytes (%; normal					
range 20-50)	22.56 (12.50-32.59)	4.53	54.78	3 (4%)	32 (42.67%)
Platelets (×10^9 per L; normal range					
125-350)	165 (132-216)	72	387	2 (2.67%)	14 (18.67%)
Haemoglobin (g/L; normal range	138(122-148.8)	78	162	18 (24%)	11 (14.67%)

115-150)					
CD4 (cell/uL; normal range 410-1590)	451 (258-760)	79	2450	3 (4%)	31 (41.33%)
CD8 (cell/uL; normal range 238-1250)	305.6 (175.3-621.5)	77.49	1914	4 (5.33%)	28 (37.33%)
CD4/CD8 (normal range 0.9-3.6)	1.4 (1.21-1.78)	0.38	4.31	1 (1.33)	11 (14.67%)
Coagulation function					
Activated partial thromboplastin time (s;					
normal range 20-40)	38.7 (34.8-43.33)	24.4	52.3	30 (40%)	0
Prothrombin time (s; normal range					
8.0-14.0)	14.5 (13.48-16.33)	10.7	19.9	44 (58.67%)	0
Blood biochemistry					
Alanine aminotransferas (IU/L; normal					
range 7-40)	23.00 (14-43)	8	171	15 (20%)	0
Aspartate aminotransferase (IU/L; norma	al				
range 13-40)	27.00 (21-37)	14	89	14 (18.67%)	0
Total bilirubin (μmol/L; normal range					
3.4-21.0)	14.50 (11.1-18.2)	3.7	55.9	12 (16%)	0
Blood urea nitrogen (mmol/L; normal					
range 2.6-7.5)	4.02 (3.03-5.41)	1.5	24.34	3 (4%)	9 (12%)
Serum creatinine (µmol/L; normal range					
41-81)	68 (58-77)	31	1561	15 (20%)	3 (4%)
Creatine kinase (IU/L; normal range					
22.0–269.0)	89.05 (54.95-150.8)	23	1063	8 (10.67%)	0
Lactate dehydrogenase (U/L; normal					
range 120-250)	233 (176.5-313)	12.5	936.0	33 (44%)	1 (1%)

Ttroponin I (ug/L; normal range 0-0.3)	0.09 (0.07-0.27)	0.03	27	13 (17.33%)	0
Infection-related biomarkers					
C-reactive protein (mg/L; normal range					
0-8.0)	13.6 (3.8-48.2)	0.5	150	46 (61.33%)	/
Erythrocyte sedimentation rate (mm/h;					
normal range 0-15) (n=45)	30.10 (11.5-69)	0.17	145	30 (66.67%)	/
Procalcitonin (ng/mL; normal range					
0-0.5) (n=59)	0.16 (0.12-0.21)	0.1	1.87	2 (3.39%)	/
Interleukin-6 (pg/mL; normal range					
0-7.0) (n=49)	6.21(5.33-7.18)	4.25	28.56	14 (28.57%)	/
Co-infection					
Adenovirus	1				

Data are median (IQR) or n/N (%). The maximum and minimum values have been presented.

Increased means over the upper limit of the normal range and decreased means below the lower

limit of the normal range.

335

336

337

Table 4. Laboratory findings of patients with elevated and normal IL-6 level

	Media		
	Elevated IL-6 (n=14)	Normal IL-6 (n=35)	P value
Blood routine			
Leucocytes (×10 ⁹ per L; normal range 3.5-9.5)	6.23 (4.13-6.86)	5.44 (3.9-6.63)	0.45
Neutrophils (×10 ⁹ per L; normal range 1.8-6.3)	5.09 (3.36-5.66)	3.43 (1.81-4.75)	0.1055
Percentage of neutrophils (%; normal range	78.02 (66.88-85.81)	70.54 (58.45-78.32)	0.0443*

40-75)			
Lymphocytes (×10 ⁹ per L; normal range 1.1-3.2)	0.79 (0.53-1.11)	1.05 (0.67-1.79)	0.1055
Percentage of Lymphocytes (%; normal range			
20-50)	14.61 (8.52-24.03)	21.58 (14.15-32.59)	0.0264*
CD4 (cell/uL; normal range 410-1590)	322 (138.5-420.5)	511.6 (242.8-816.5)	0.0367*
CD8 (cell/uL; normal range 238-1250)	153.4 (119.2-228.4)	305.4 (179.6-651.8)	0.0021*
CD4/CD8 (normal range 0.9-3.6)	1.57 (0.930-2.46)	1.41 (0.53-1.78)	0.2081
Blood biochemistry			
Alanine aminotransferas (IU/L; normal range			
7-40)	27.5 (13.5-43.75)	23 (16.00-47)	0.9782
Aspartate aminotransferase (IU/L; normal range			
13-40)	27 (21.75-39.50)	28 (20-38)	0.6028
Total bilirubin (μmol/L; normal range 3.4-21.0)	13.45 (9.38-16.45)	14.3 (10.7-18.3)	0.5217
Serum creatinine (µmol/L; normal range 41-81)	72.5 (59.75-81.75)	67 (60-79)	0.5727
Creatine kinase (IU/L; normal range 22.0–269.0)	86.2 (66.95-240.3)	92.85 (56.45-144.3)	0.6619
Lactate dehydrogenase (U/L; normal range			
120-250)	318 (252.5-408.8)	230 (177.8-319.3)	0.027*
Ttroponin I (ug/L; normal range 0-0.3)	0.26(0.09-0.77)	0.08 (0.07-0.29)	0.0955
Infection-related biomarkers			
C-reactive protein (mg/L; normal range 0-8.0)	76.45 (21.53-110.5)	9.0 (3.26-23.10)	0.0003*
Erythrocyte sedimentation rate (mm/h; normal			
range 0-15)	69 (19.50-115.4)	29.10 (13.40-62.25)	0.127
Procalcitonin (ng/mL; normal range 0-0.5)	0.23 (0.17-0.29)	0.15 (0.11-0.18)	0.0017*

Abbreviation: IL-6, Interleukin-6. Data are presented as median (IQR) or n/N (%). Statistical analysis, Mann-Whitney test. P values indicate differences between patients with elevated and normal IL-6 level. * P < .05 was considered statistically significant.

Figure legend

Figure 1. Differences of laboratory findings between patients with elevated and normal IL-6 level.

(a) Percentage of NEU and LYM, (b) CD4+ and CD8+ T cell counts, (c) Detection of LDH levels, and (d) Changes of the infection indicator, CRP in two groups. Data are presented as median (interquartile range, IQR) and analyzed by Mann-Whitney test. All statistical analyses were performed using GraphPad Prism 8.3. P values indicate differences between patients with elevated and normal IL-6 level (* p<.05, ** p<.005, *** p<.001). P <.05 was considered statistically significant.

Abbreviations: IL-6, Interleukin-6; lymphocytes percentage, LYM%; neutrophil percentage,

NEU%; lactate dehydrogenase, LDH; C-reactive protein, CRP.

LDH

LDH

CRP